Asymchem Laboratories Tian Jin Co Ltd (002821) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Asymchem Laboratories Tian Jin Co Ltd (002821) has a cash flow conversion efficiency ratio of 0.026x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥449.89 Million ≈ $65.83 Million USD) by net assets (CN¥17.36 Billion ≈ $2.54 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Asymchem Laboratories Tian Jin Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Asymchem Laboratories Tian Jin Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 002821 liabilities breakdown for a breakdown of total debt and financial obligations.
Asymchem Laboratories Tian Jin Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Asymchem Laboratories Tian Jin Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ningbo Zhenyu Technology Co. Ltd.
SHE:300953
|
0.016x |
|
Hyundai Mipo Dockyard
KO:010620
|
0.085x |
|
United Integrated Services Co Ltd
TW:2404
|
0.448x |
|
Amdocs Limited
F:AOS
|
0.064x |
|
Bank Millennium S.A.
WAR:MIL
|
0.199x |
|
The People's Insurance Company (Group) of China Limited
F:PIR
|
0.077x |
|
Hyundai Construction Equipment Co Ltd
KO:267270
|
0.030x |
|
Ramsay Health Care Ltd
AU:RHC
|
0.207x |
Annual Cash Flow Conversion Efficiency for Asymchem Laboratories Tian Jin Co Ltd (2011–2025)
The table below shows the annual cash flow conversion efficiency of Asymchem Laboratories Tian Jin Co Ltd from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Asymchem Laboratories Tian Jin Co Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥17.65 Billion ≈ $2.58 Billion |
CN¥1.41 Billion ≈ $205.97 Million |
0.080x | +7.23% |
| 2024-12-31 | CN¥16.86 Billion ≈ $2.47 Billion |
CN¥1.25 Billion ≈ $183.55 Million |
0.074x | -63.31% |
| 2023-12-31 | CN¥17.51 Billion ≈ $2.56 Billion |
CN¥3.55 Billion ≈ $519.44 Million |
0.203x | -3.20% |
| 2022-12-31 | CN¥15.70 Billion ≈ $2.30 Billion |
CN¥3.29 Billion ≈ $480.98 Million |
0.209x | +2233.93% |
| 2021-12-31 | CN¥12.61 Billion ≈ $1.85 Billion |
CN¥113.15 Million ≈ $16.56 Million |
0.009x | -90.56% |
| 2020-12-31 | CN¥5.99 Billion ≈ $876.49 Million |
CN¥569.29 Million ≈ $83.31 Million |
0.095x | -51.83% |
| 2019-12-31 | CN¥3.05 Billion ≈ $445.65 Million |
CN¥600.87 Million ≈ $87.93 Million |
0.197x | +19.34% |
| 2018-12-31 | CN¥2.51 Billion ≈ $367.38 Million |
CN¥415.06 Million ≈ $60.74 Million |
0.165x | +81.41% |
| 2017-12-31 | CN¥2.16 Billion ≈ $315.35 Million |
CN¥196.40 Million ≈ $28.74 Million |
0.091x | -39.99% |
| 2016-12-31 | CN¥1.83 Billion ≈ $268.22 Million |
CN¥278.36 Million ≈ $40.73 Million |
0.152x | -44.63% |
| 2015-12-31 | CN¥937.02 Million ≈ $137.12 Million |
CN¥256.99 Million ≈ $37.61 Million |
0.274x | +69.50% |
| 2014-12-31 | CN¥785.17 Million ≈ $114.90 Million |
CN¥127.05 Million ≈ $18.59 Million |
0.162x | +4.81% |
| 2013-12-31 | CN¥686.10 Million ≈ $100.40 Million |
CN¥105.92 Million ≈ $15.50 Million |
0.154x | +173.00% |
| 2012-12-31 | CN¥608.06 Million ≈ $88.98 Million |
CN¥34.38 Million ≈ $5.03 Million |
0.057x | +18.47% |
| 2011-12-31 | CN¥542.26 Million ≈ $79.35 Million |
CN¥25.88 Million ≈ $3.79 Million |
0.048x | -- |
About Asymchem Laboratories Tian Jin Co Ltd
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, incl… Read more